BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36970720)

  • 21. Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ.
    Liu Y; Yu T
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11181-11191. PubMed ID: 37354223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic Value of Ultrasound Elastography in the Differentiation of Breast Invasive Ductal Carcinoma and Ductal Carcinoma
    Shi J; Chen L; Wang B; Zhang H; Xu L; Ye J; Liu Y; Shao Y; Sun X; Zou Y
    Curr Med Imaging; 2023; 19(3):286-291. PubMed ID: 35899956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifying ductal carcinoma in situ cases not requiring surgery to exclude postoperative upgrade to invasive ductal carcinoma.
    Nakayama S; Masuda H; Miura S; Kuwayama T; Hashimoto R; Taruno K; Sawada T; Akashi-Tanaka S; Nakamura S
    Breast Cancer; 2022 Jul; 29(4):610-617. PubMed ID: 35278202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
    Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
    Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.
    Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B
    Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different distribution of breast ductal carcinoma in situ, ductal carcinoma in situ with microinvasion, and invasion breast cancer.
    Zhang W; Gao EL; Zhou YL; Zhai Q; Zou ZY; Guo GL; Chen GR; Zheng HM; Huang GL; Zhang XH
    World J Surg Oncol; 2012 Dec; 10():262. PubMed ID: 23216911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of breast MRI for surgical decision in patients with breast cancer: ductal carcinoma in situ versus invasive ductal carcinoma.
    Lee J; Jung JH; Kim WW; Park CS; Lee RK; Kim HJ; Kim WH; Park HY
    BMC Cancer; 2020 Sep; 20(1):934. PubMed ID: 32993586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histogram analysis of volume-based apparent diffusion coefficient in breast cancer.
    Park GE; Kim SH; Kim EJ; Kang BJ; Park MS
    Acta Radiol; 2017 Nov; 58(11):1294-1302. PubMed ID: 28273747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.
    Van Bockstal MR; Agahozo MC; Koppert LB; van Deurzen CHM
    Int J Cancer; 2020 Mar; 146(5):1189-1197. PubMed ID: 31018242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does concomitant ductal carcinoma in situ affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: An Asian perspective.
    Lee WP; Shetty SS; Seah CMJ; Tan PT; Tan SM
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1646. PubMed ID: 35892151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic predisposition to ductal carcinoma in situ of the breast.
    Petridis C; Brook MN; Shah V; Kohut K; Gorman P; Caneppele M; Levi D; Papouli E; Orr N; Cox A; Cross SS; Dos-Santos-Silva I; Peto J; Swerdlow A; Schoemaker MJ; Bolla MK; Wang Q; Dennis J; Michailidou K; Benitez J; González-Neira A; Tessier DC; Vincent D; Li J; Figueroa J; Kristensen V; Borresen-Dale AL; Soucy P; Simard J; Milne RL; Giles GG; Margolin S; Lindblom A; Brüning T; Brauch H; Southey MC; Hopper JL; Dörk T; Bogdanova NV; Kabisch M; Hamann U; Schmutzler RK; Meindl A; Brenner H; Arndt V; Winqvist R; Pylkäs K; Fasching PA; Beckmann MW; Lubinski J; Jakubowska A; Mulligan AM; Andrulis IL; Tollenaar RA; Devilee P; Le Marchand L; Haiman CA; Mannermaa A; Kosma VM; Radice P; Peterlongo P; Marme F; Burwinkel B; van Deurzen CH; Hollestelle A; Miller N; Kerin MJ; Lambrechts D; Floris G; Wesseling J; Flyger H; Bojesen SE; Yao S; Ambrosone CB; Chenevix-Trench G; Truong T; Guénel P; Rudolph A; Chang-Claude J; Nevanlinna H; Blomqvist C; Czene K; Brand JS; Olson JE; Couch FJ; Dunning AM; Hall P; Easton DF; Pharoah PD; Pinder SE; Schmidt MK; Tomlinson I; Roylance R; García-Closas M; Sawyer EJ
    Breast Cancer Res; 2016 Feb; 18(1):22. PubMed ID: 26884359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials.
    Alaeikhanehshir S; Voets MM; van Duijnhoven FH; Lips EH; Groen EJ; van Oirsouw MCJ; Hwang SE; Lo JY; Wesseling J; Mann RM; Teuwen J;
    Cancer Imaging; 2024 Apr; 24(1):48. PubMed ID: 38576031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic performance of minimum apparent diffusion coefficient value in differentiating the invasive breast cancer and ductal carcinoma
    Zhao S; Shao G; Chen P; Li L; Yang Y; Zhao X; Guo W
    J Cancer Res Ther; 2019; 15(4):871-875. PubMed ID: 31436245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis.
    Ploumen RAW; de Mooij CM; Gommers S; Keymeulen KBMI; Smidt ML; van Nijnatten TJA
    Eur Radiol; 2023 Aug; 33(8):5423-5435. PubMed ID: 37020070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of coexisting invasive carcinoma on ductal carcinoma in situ (DCIS) lesions by mass spectrometry imaging.
    Chen H; Li X; Li F; Li Y; Chen F; Zhang L; Ye F; Gong M; Bu H
    J Pathol; 2023 Oct; 261(2):125-138. PubMed ID: 37555360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH.
    Aubele M; Mattis A; Zitzelsberger H; Walch A; Kremer M; Welzl G; Höfler H; Werner M
    Int J Cancer; 2000 Jan; 85(1):82-6. PubMed ID: 10585588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of heterozygosity analyses of asynchronous lesions of ductal carcinoma in situ and invasive ductal carcinoma of the human breast.
    Amari M; Moriya T; Ishida T; Harada Y; Ohnuki K; Takeda M; Sasano H; Horii A; Ohuchi N
    Jpn J Clin Oncol; 2003 Nov; 33(11):556-62. PubMed ID: 14711979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of clinicopathological characteristics and prognosis among patients with pure invasive ductal carcinoma, invasive ductal carcinoma coexisted with invasive micropapillary carcinoma, and invasive ductal carcinoma coexisted with ductal carcinoma in situ: A retrospective cohort study.
    Guan X; Xu G; Shi A; Zou Y; Zhan Y; Fan Z; Dong Y
    Medicine (Baltimore); 2020 Dec; 99(50):e23487. PubMed ID: 33327281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imaging of lumpectomy surface with large field-of-view confocal laser scanning microscope for intraoperative margin assessment - POLARHIS study.
    Sandor MF; Schwalbach B; Hofmann V; Istrate SE; Schuller Z; Ionescu E; Heimann S; Ragazzi M; Lux MP
    Breast; 2022 Dec; 66():118-125. PubMed ID: 36240525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ.
    Meyerson AF; Lessing JN; Itakura K; Hylton NM; Wolverton DE; Joe BN; Esserman LJ; Hwang ES
    Breast; 2011 Dec; 20(6):529-33. PubMed ID: 21843942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.